Compared with traditional biomarkers such as chromogranin A (CgA), ctDNA offers the distinct advantage of directly reflecting the tumor’s molecular landscape, potentially allowing earlier detection of disease progression [87]. The gene discussed is CGA; the disease is neoplasm.